Stemedica’s Clinical Trial Using Cryoport Logistics
Companies expand agreement as biotech firm Stemedica uses Cryoport shippers and monitoring systems for a new Phase II clinical trial to assess a stem cell therapy for the treatment of Alzheimer’s disease.
Regenerative medicine and the use of stem cells and biologics offer considerable promise for the treatment of conditions including heart disease, Alzheimer’s, Parkinson’s, stroke, wound care and diabetes.
One of the companies on the leading edge of this technology is Stemedica Cell Technologies, Inc., which develops and manufactures ischemic-tolerant allogeneic stem cells that support pre-clinical and clinical studies primarily in the areas of neurology, cardiology, ophthalmology and dermatology.
The San Diego-based global biopharmaceutical firm will conduct a Phase II clinical trial to assess the safety, tolerability and preliminary efficacy of allogeneic stem cell-based therapies in the treatment of Alzheimer’s disease. Supporting that effort is cryogenic logistics company Cryoport, which recently expanded its contract with Stemedica.
Source: Logistics for the Life Sciences
